Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Liabilities and Shareholders Equity of $2.11 billion for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 53.0% from $1.38 billion a year earlier but down 6.9% from the prior quarter.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
At the end of FY2025 (ended Sep 30, 2025), Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity came in at $1.39 billion, up 21.5% from FY2024.
- Annual Liabilities and Shareholders Equity has increased for three consecutive fiscal years, with a five-year compound annual growth rate of 21.5% (FY2020 to FY2025).
- In prior fiscal years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity was $1.14 billion in FY2024 (+48.9%), $765.55 million in FY2023 (+10.6%), $691.94 million in FY2022 (-2.6%) and $710.15 million in FY2021 (+35.9%).
- Quarterly Liabilities and Shareholders Equity has run from a low of $626.29 million in fiscal Q1 2024 to a high of $2.27 billion in fiscal Q2 2026 over five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last ten quarters, with growth averaging 51.1% over the last eight quarters.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was fiscal Q2 2025, with growth of 64.7%; the weakest was fiscal Q1 2024, with a decline of 29.7%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior fiscal quarters was $2.27 billion (Q2 2026), $1.6 billion (Q1 2026) and $1.39 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Arrowhead Pharmaceuticals | 9.24 Bn | 4.02 Bn | - | 2.11 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.11 Bn |
| Mar 31, 2026 | 2.27 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 1.39 Bn |
| Jun 30, 2025 | 1.38 Bn |
| Mar 31, 2025 | 1.57 Bn |
| Dec 31, 2024 | 1.01 Bn |
| Sep 30, 2024 | 1.14 Bn |
| Jun 30, 2024 | 883.76 Mn |
| Mar 31, 2024 | 955.15 Mn |
| Dec 31, 2023 | 626.29 Mn |
| Sep 30, 2023 | 765.55 Mn |
| Jun 30, 2023 | 795.86 Mn |
| Mar 31, 2023 | 891.31 Mn |
| Dec 31, 2022 | 891.49 Mn |
| Sep 30, 2022 | 691.94 Mn |
| Jun 30, 2022 | 751.78 Mn |
| Mar 31, 2022 | 703.58 Mn |
| Dec 31, 2021 | 638.54 Mn |
| Sep 30, 2021 | 710.15 Mn |
API Access
Arrowhead Pharmaceuticals Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ARWR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ARWR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ARWR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();